Monday, 28 August 2017

CEO Dennis Calvert Gives a Personal Interview on the Symposium’s Positive Outcome and BioLargo’s Current Accomplishments


Westminster, CA , Aug. 28, 2017 (GLOBE NEWSWIRE) -- Mr. Dennis Calvert, CEO of BioLargo, Inc. (OTCQB:BLGO), interviews on the Uptick Network with host Everett Jolly. Mr. Calvert gives a personal interview on BioLargo’s third annual technical symposium and the science behind its AOS (Advanced Oxidation System). Mr. Calvert elaborates on the Alpha unit’s performance on client-provided water from poultry, dairy, and municipal wastewater, and explains the data outcome that the AOS is proven to solve specific problems and what this could mean for the marketplace. With presenting four other designs at the symposium, Mr. Calvert clarifies how the designs work and that some were tested to show the effectiveness and the multiple purposes that these devices accomplish.
Mr. Calvert also reviewed the status of the company’s medical technologies, commenting on subsidiary Clyra Medical’s efforts and accomplishments, including the status of FDA filings and what this means for the company and product. For industrial odor, Mr. Calvert reviews the hardships of the introduction of CupriDyne Clean to the markets and explains how the growth of the product is being accepted in the market now and what this means for BioLargo’s future.
In closing Mr. Calvert states, “The point for investors is to understand that this is a highly evolving company, with a bright future, a great opportunity and we are narrowing and focusing to execute on high value proposition. The opportunity are so expansive that if you look at us today and you wait 6 months the company is literally morphing every 6 months into this machine that has this momentum, the talent, the infrastructure, and all the tools to execute. So we’re very excited and thank you for all the support.”
About BioLargo, Inc.
BioLargo, Inc. (BLGO)  is a sustainable science and technology company that makes life better by delivering award-winning products for clean water, clean air and advanced wound care. More information can be found about the company and its subsidiaries at www.BioLargo.com. Its subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo's subsidiary Odor-No-More Inc., features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that must contend with malodors, VOC’s or similar air quality related problems. Its personal care products are finding adoption through white labeling or early market entry in the pet, equine, military supply and consumer markets, and include the Nature's Best Solution® and Deodorall® brands (www.OdorNoMore.com). BioLargo's subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced wound care management featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc.

Friday, 25 August 2017

BioLargo a Title Sponsor at Sustain OC's Water Solutions 2 Conference - August 29 at UC Irvine

We are excited to say that BioLargo will be a Title Sponsor at the upcoming Sustain OC event, Water Solutions 2, held at the world-renowned UC Irvine campus on Tuesday, August 29, 2017! The event's other Title Sponsor will be the Metropolitan Water District (MWD) of Southern California, a leading innovator in water resource management and technologies. 








The event will focus on some of the emerging technologies being developed in the Orange County area, as well as some of the important challenges that water technology innovators face in today's market place. BioLargo CEO Dennis Calvert will moderate a presentation session given by 14 water technology companies, and will also present BioLargo's exciting story of its revolutionary Advanced Oxidation System.

For more info on the companies attending (including big names like Sloan!), and for more info on the program, go here.

Some examples of topics will be:
  • Trends in Water Tech Investments: Public and Private Investor Perspectives
  • Smart Water Tech: Data Acquisition & Usage
  • Cutting Down on the Adoption Cycle










This will be a tremendous opportunity to learn about the exciting innovators in the OC region who, along with Sustain OC and BioLargo, are working to build the foundation of tomorrow's sustainable clean water market.

Monday, 21 August 2017

BioLargo’s Third Annual Technical Symposium Showcases its Advanced Oxidation System (AOS) and First Commercial Validation Trials Performance Results



August 21, 2017 – Our 3rd annual technical symposium was a huge success! There we announced that performance validation testing of our AOS system in collaboration with a major engineering firm on industry-provided water samples from a poultry farm, a dairy farm, and a major west coast municipality showed it beat the “best in industry” performance metrics on both disinfection and energy use. 

AOS used in commercial validation trials
We gave symposium attendees, which included stakeholders, industry experts, government representatives, and renowned academics, a glimpse of AOS scale-up design options to manage higher flow rates for a wide range of potential industrial and municipal customers. These design options include compact AOS reactors in their current physical configuration in an array (below, top), as well as fluid bed designs for low-footprint, low-pressure processing (below, bottom). With these preliminary designs and proper funding in place, we are ready to roll up our sleeves and get down to the practical engineering work required to produce client-ready buildable “beta” designs. 

The symposium also showcased the AOS’ efficient removal of some difficult-to-treat micro pollutants, compelling evidence of complete virus elimination, and three independent academic studies that help explain why the AOS achieves such astounding oxidation rates. We were also pleased to report promising results for the removal of BOD (Biological Oxygen Demand) concurrent with high-level disinfection, a remarkable and rare value proposition for water treatment systems. More than 30 scientists, collaborators, and students were a part of these studies, all of which were funded by provincial or federal Canadian or US grants.

AOS 500 gpm array of canisters design
AOS fluid bed design for batch processing




















AOS Mini (solar-powered)
In keeping with BioLargo’s mission to “Make Life Better”, BioLargo’s team of talented engineers debuted and demonstrated a solar-powered AOS prototype.  With some development, the AOS Mini has the potential to inexpensively provide clean water in extremely water-scarce or disaster-prone areas. The ability to use a small solar array to power a water filter of this caliber highlights the flexible design and ultra low power requirements of the AOS, and was commented as “incredible” by conference attendees.

The company’s Chief Science Officer, Kenneth R. Code pointed out, “With continued validation from academics and leading water engineers in North America that our science is now proven effective and that it can offer a low-cost alternative to incumbent technologies. Data continues to point to the AOS as a best in class water treatment solution. We are poised to advance our system with engineering for commercial on-site trials.”

Dennis P. Calvert, BioLargo’s President & CEO commented, “We are also thankful for our shareholders that consistently support our mission to Make Life Better and deliver value to our stakeholders. Our exceptional team continues to break records and set new high standards. Our future is bright as we continually advance and refine all of our sustainable solutions for clean water, clean air and advanced wound care”. 

Attendees at Agri-Food Discovery Place- our research facility














About BioLargo, Inc.

BioLargo, Inc. (BLGO) is a sustainable science and technology company that makes life better by delivering award-winning products for clean water, clean air and advanced wound care. More information can be found about the company and its subsidiaries at www.BioLargo.com. Its subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo's subsidiary Odor-No-More Inc., features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that must contend with malodors, VOC’s or similar air quality related problems. Its personal care products are finding adoption through white labeling or early market entry in the pet, equine, military supply and consumer markets, and include the Nature's Best Solution® and Deodorall® brands (www.OdorNoMore.com). BioLargo's subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced wound care management featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc.



Safe Harbor Statement

The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K for the year ended December 31, 2016.


Company Contact

Dennis Calvert
President and CEO
BioLargo, Inc.
949-643-9540 x1
 

widget